Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Feb 12;24(3):640.
doi: 10.3390/molecules24030640.

Therapeutic Radiometals: Worldwide Scientific Literature Trend Analysis (2008⁻2018)

Licia Uccelli  1   2 , Petra Martini  3   4 , Corrado Cittanti  5   6 , Aldo Carnevale  7   8 , Loretta Missiroli  9 , Melchiore Giganti  10   11 , Mirco Bartolomei  12 , Alessandra Boschi  13
Affiliations

Therapeutic Radiometals: Worldwide Scientific Literature Trend Analysis (2008⁻2018)

Licia Uccelli et al. Molecules. .

Erratum in

Abstract

Academic journals have published a large number of papers in the therapeutic nuclear medicine (NM) research field in the last 10 years. Despite this, a literature analysis has never before been made to point out the research interest in therapeutic radionuclides (RNs). For this reason, the present study aims specifically to analyze the research output on therapeutic radiometals from 2008 to 2018, with intent to quantify and identify global trends in scientific literature and emphasize the interdisciplinary nature of this research field. The data search targeted conventional (131I, 90Y, 177Lu, 188Re, 186Re, 153Sm, 89Sr, 186Er) and emergent (67Cu, 47Sc, 223Ra, 166Ho, 161Tb, 149Tb, 212Pb/212Bi, 225Ac, 213Bi, 211At, 117mSn) RNs. Starting from this time frame, authors have analyzed and interpreted this scientific trend quantitatively first, and qualitatively after.

Keywords: radionuclide therapy; therapeutic radiometals; therapeutic radiopharmaceuticals.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
A comparison between the annual publication number of CRNs vs. ERNs (2008–2018). Total number of papers = 12717; total number of papers on CRNs = 10339; total number of papers on ERNs = 2378.
Figure 2
Figure 2
Graphical representation of the annual publications discussing CRNs (2008–2018).
Figure 3
Figure 3
Graphical representation of the annual publications discussing ERNs (2008–2018).
Figure 4
Figure 4
CRN macro-areas contribution (2008–2018).
Figure 5
Figure 5
ERN macro-areas contribution (2008–2018).
Figure 6
Figure 6
Graphical representation of the worldwide contribution to publications discussing CRNs and ERNs.
Figure 7
Figure 7
The top 20 countries most contributing to conventional radionuclide publications (2008–2018).
Figure 8
Figure 8
The top 20 countries most contributing to emergent radionuclide publications (2008–2018).
See this image and copyright information in PMC

References

    1. Engle J.W. The Production of Ac-225. Curr. Radiopharm. 2018 doi: 10.2174/1874471011666180418141357. - DOI - PubMed
    1. McDevitt M.R., Sgouros G., Sofou S. Targeted and Nontargeted α-Particle Therapies. Annu. Rev. Biomed. Eng. 2018;20:73–93. doi: 10.1146/annurev-bioeng-062117-120931. - DOI - PMC - PubMed
    1. Poty S., Francesconi L.C., McDevitt M.R., Morris M.J., Lewis J.S. α-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies-Part 1. J. Nucl. Med. 2018;59:878–884. doi: 10.2967/jnumed.116.186338. - DOI - PMC - PubMed
    1. Marcu L., Bezak E., Allen B.J. Global comparison of targeted alpha vs targeted beta therapy for cancer: In vitro, in vivo and clinical trials. Crit. Rev. Oncol. Hematol. 2018;123:7–20. doi: 10.1016/j.critrevonc.2018.01.001. - DOI - PubMed
    1. Kozempel J., Mokhodoeva O., Vlk M. Progress in Targeted Alpha-Particle Therapy. What We Learned about Recoils Release from In Vivo Generators. Molecules. 2018;23:581. doi: 10.3390/molecules23030581. - DOI - PMC - PubMed